About this Research Topic
Vaccines are important tools for global health, reducing disability and death, and saving billions in public health costs by preventing disease. Although new technologies for vaccines have developed immensely in the last decades, the discovery of new vaccines has been limited. However, these efforts have paved the way for the global effort to develop vaccines to control the SARS-CoV-2 virus, and almost ten vaccines are available for phase III usage in record time, some of them using innovative technologies, as messenger RNA or non-replicating recombinant adenovirus. These tools of modern vaccinology open opportunities for the development of vaccines against neglected tropical diseases (NTD) of medical importance that afflicts 1.1 billion people worldwide. The scarcity of vaccines for NTD, and the potential impact of COVID-19 pandemic on the burden of these diseases, prompted us into this Research Topic on advances in vaccine development against the protozoan parasites Trypanosoma cruzi, Leishmania spp., and Plasmodium vivax.
With this Research Topic we aim at gathering recent advances in the development of vaccines against protozoa of great medical importance, such as those causing leishmaniasis, Chagas disease and malaria. Moreover, submissions on other protozoan parasites lacking vaccines are encouraged.
We welcome the submissions of Original Research, Review, Perspective, and Clinical trials articles covering, but not limited to, the following topics:
• Antigen delivery systems
• Adjuvants for human use
• Vaccine formulations containing Toll-like Receptor (TLR) agonists
• Technologies for stable genetic manipulations
• Immunogenicity and proof of concept
• Preclinical trial related to the development of vaccines against protozoa parasites
• Human Clinical trial related to the development of vaccines against protozoa parasites
• Immune correlates of protection against protozoa parasites
• Systems biology approaches of vaccination against protozoa parasites.
Keywords: Recombinant protein, adjuvants, virus-like particles, viral vectors, nucleic acid vaccines, B and T cell immune responses, preclinical trial, clinical trial, bioinformatics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.